Found: 6
Select item for more details and to access through your institution.
MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S2, doi. 10.1016/j.clml.2017.09.025
- By:
- Publication type:
- Article
Upregulation of MCL-1 through MAPK Activation Maintaining Mitochondrial Oxidative Phosphorylation Confers Acquired Resistance to BCL-2 Inhibitor Venetoclax in AML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S285, doi. 10.1016/j.clml.2017.07.069
- By:
- Publication type:
- Article
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- Signal Transduction & Targeted Therapy, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41392-021-00870-3
- By:
- Publication type:
- Article
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- Signal Transduction & Targeted Therapy, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41392-021-00870-3
- By:
- Publication type:
- Article
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.
- Published in:
- Signal Transduction & Targeted Therapy, 2022, v. 7, n. 1, p. 1, doi. 10.1038/s41392-021-00870-3
- By:
- Publication type:
- Article